AB0744 HOW JUVENILE IDIOPATHIC ARTHRITIS PATIENTS PERCEIVE THEIR ILLNESS?

Background:Juvenile idiopathic arthritis (JIA) represents the most common inflammatory rheumatism of childhood. Because of a prolonged course of active disease, many patients experience physical and psychosocial limitations. Illness perceptions involve the personal beliefs that patients have about their illness and may influence health behaviors considerably.Objectives:The present study aimed to investigate the illness perception of patients with JIA.Methods:We conducted a cross-sectional study including children with JIA (according to the International League of Associations for Rheumatology (ILAR)). We recorded sociodemographic data and the subtype of the JIA. To assess a child’s perception of how arthritis affects their life, the Brief Illness Perception Questionnaire (IPQ) was completed by the parent (child age ≤10 years) or by the child (age ≥11 years). The Brief IPQ is a nine-item questionnaire rated using a 0-to10 response scale that assesses cognitive illness representations: consequences (Item 1), timeline (Item 2), personal control (Item 3), treatment control (Item 4), and identity (Item 5). Two of the items assess emotional representations: concern (Item 6) and emotions (Item 8). One item assesses illness comprehensibility (Item 7).Results:The study included 22 patients. The mean age was 15 ± 7 years [4-35], and the mean age at diagnosis was 9 ±3 years [3-14]. There was a female predominance (sex ratio= 2.1). The frequency of each JIA subset was at follows: polyarticular with rheumatoid factor (n= 1), polyarticular without rheumatoid factor (n=3), systemic (n= 2), enthesitis-related arthritis (n=9), oligoarthritis (n= 7), undifferentiated (n=1). Non-steroidal anti-inflammatory drugs were prescribed in 72% of cases, and Cs-DMARDs in 59% of patients. The most-reported causal factor in their illness was a history of traumatism (22%). Perceiving symptoms (identity) were significantly related to being affected by the disease (emotional response) (p= 0.01). Conversely, patients who had personal and treatment control expressed less emotional response (r = −0.7, r=-0.2 respectively). Moreover, those who were concerned about the disease perceived more the consequences of their illness (p=0.09) and understood it more (p=0.029). We also noted significant correlations between personal control and treatment control (p = 0.033). A positive correlation was found between identity as well as consequences and timeline (p=0.011, p=0.024), showing that the perception of chronicity was associated with pain and the burden of the disease.Conclusion:Our study highlighted the importance of assessing illness perception in JIA patients. Patient education programs should be implemented since diagnosis for better disease management.Disclosure of Interests:None declared

Detection of Fake Online Reviews Using Semi-Supervised and Supervised Learning

Online reviews have an incredible effect on the present business and trade. The development of web-based business organizations has pulled in numerous buyers since they provide a scope of items on aggressive costs. The main aspect most buyers depends on while doing online shopping is the review of items for closing the choice of object. Basic leadership for the acquisition of online items generally relies upon reviews given by the clients. Henceforth, deft people or gatherings attempt to control item surveys for their advantages. In perspective on the impacts of these phony surveys, various systems to recognize these were proposed in the research. Because of reviews and its nature, this is hard to group these utilizing only one classifier. Henceforth, the present research discusses a classifier for dealing with identifying such phony reviews. The study also presents the text mining techniques both supervised and semi-supervised to identify counterfeit online reviews just as looks at the effectiveness of the two strategies on the datasets with hotel surveys.

Improve the Electrical Properties of the ITO-PET Polymer by Plasma Technique

At present the applications of the conductive polymer are monitor, batteries and the sensors but there have been limitations due to the manufacturing costs, material inconsistencies, toxicity, poor solubility in solvents, and inability to directly melt process. Regarding these problems, in this research to studies the condition to enhance the conductive polymer were conducted via the carbon dioxide plasma technique coated on ITO-PET. The plasma power is 50, 75, 100, 125 and 150 watts in the vacuum conditions for periods 10, 20 and 30 mins respectively. The electrical properties were measured via the 4 point probe. The contact angle for analyzing the hydrophobic was analyzed. The result demonstrated that the power of the plasma and the time has influence on the conductive polymer. With the time for doping at 20 mins the current increased compare to the control item. However, with the time doping at 10 and 30 mins the current decreased. The maximum current at 10 mins doping is 22 mA at the 7 volts in the conduction of 75 watts plasma power. The contact angle of the ITO-PET polymer decrease from 110 degree to 44-95 degree. Henceforth when using the carbon dioxide plasma the phenomenal of hydrophilic increases.

Preclinical Efficacy Testing of Baxter's Recombinant FVIIa

Abstract 4659 Baxter has developed a recombinant FVIIa (rFVIIa) product for the treatment of patients with hemophilia A and hemophilia B with inhibitors. The aim of the presented preclinical studies was to evaluate the efficacy of Baxter's rFVIIa. Four animal models that are considered to relevantly reflect the conditions in different patient populations were used: hemophilia A (FVIII ko) mice, hemophilia B (FIX ko) mice, factor VIII (FVIII)-inhibited rabbits and warfarin-pretreated rats. In all studies, Baxter's rFVIIa was tested at different doses to obtain dose-effect curves. A commercially available rFVIIa served as the active control item, buffer served as the negative control item. All test and control items were administered intravenously. Mice received prophylactic treatment 5 minutes prior to start of the experiment, rabbits and rats received therapeutic treatment after the injuries were inflicted. Twenty FVIII ko mice (B6;129S4-F8tm1Kaz; 10m/10f) and 20 FIX ko mice (B6;129P2-F9tm1Dws; 10m/10f) per group were used in a tail-tip bleeding model. Baxter's rFVIIa was tested at doses of 0.6, 1.2 and 2.7 mg/kg, the active control item was tested at a dose of 2.7 mg/kg. Ten FVIII ko mice (B6;129S4-F8tm1Kaz; 5m/5f) per group were used to assess the influence of rFVIIa on the thrombelastogram of hemophilic mice. Both items were tested at doses of 0.1, 0.6 and 1.2 mg/kg. Six rabbits (New Zealand White; 6m) per group were used in a nail-cut model. The animals were pretreated with a goat polyclonal FVIII-antibody (34,000 BU/kg i.v., 45 minutes prior to start of the experiment), leading to deficiency of endogenous FVIII. Baxter's new rFVIIa was tested at doses of 0.1, 1.0, 2.0, 2.5 and 3.0 mg/kg, the active control item at 2.0 mg/kg. Six rats (Sprague Dawley; 6m) per group were used in a tail-tip bleeding model. The animals were pretreated with warfarin (11 mg p.o., 1 day prior to start of the experiment), leading to a deficiency of vitamin K-dependent coagulation factors II, VII, IX and X, protein C and protein S. Baxter's new rFVIIa was tested at 0.25, 1.0 and 2.0 mg/kg, the active control item at 2.0 mg/kg. A dose-dependent hemostatic effect of Baxter's new rFVIIa could be shown in all primary pharmacodynamic studies performed. Furthermore, statistical evaluation of the efficacy of Baxter's new rFVIIa did not reveal any statistically significant differences from the commercially available rFVIIa product after treatment at the same doses. In summary, the results of our studies show that Baxter's new rFVIIa is prophylactically and therapeutically effective in animal models of efficacy closely reflecting the conditions in hemophiliacs with inhibitors and patients suffering from FVII-deficiency. Disclosures: Schiviz: Baxter Innovations GmbH: Employment. Lawo:Baxter Innovations GmbH: Employment. Resch:Baxter Innovations GmbH: Employment. Leidenmuehler:Baxter Innovations GmbH: Employment. Bischetsrieder:Baxter Innovations GmbH: Employment. Ehrlich:Baxter Innovations GmbH: Employment. Scheiflinger:Baxter Innovations GmbH: Employment. Schwarz:Baxter Innovations GmbH: Employment. Hoellriegl:Baxter Innovations GmbH: Employment. Muchitsch:Baxter Innovations GmbH: Employment.